In an interview, Moderna’s President Stephen Hoge said that he expects its COVID vaccine to be priced at around $130 in the US.
Moderna Inc (MRNA.O) expects to price its COVID-19 vaccine at around $130 per dose in the U.S. going forward as purchases move to the private sector from the government, the company’s president Stephen Hoge said in an interview on Monday.
“There are different customers negotiating different prices right now, which is why it’s a little bit complicated,” Hoge said ahead of a Congressional hearing run by Democratic U.S. Senator Bernie Sanders on Moderna’s pricing plans.
Moderna previously said it was considering pricing its COVID vaccine in a range of $110 to $130 per dose in the United States, similar to the range Pfizer Inc (PFE.N) said in October it was considering for its rival COVID shots sold in partnership with BioNTech (22UAy.DE).
Hoge said the government’s Medicare health plan for seniors pays $70 per dose for the seasonal influenza vaccine. That there were two to three times more hospitalizations and deaths from COVID in the past three months alone than from the flu went into the company’s pricing reasoning, Hoge said.
Subscribe to GreatGameIndia
In a court filing last month, Department of Justice lawyers offered to “relieve” Moderna of any liability it faces from a lawsuit that accuses the drug company of failing to pay licensing fees for technology it used to develop its vaccine during “Operation Warp Speed.”
You can read more about this topic here.